Trials / Unknown
UnknownNCT02678299
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University of Aarhus · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab (P\[R\]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.
Detailed description
This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab (P\[R\]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PREBEN |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2022-02-01
- Completion
- 2025-12-01
- First posted
- 2016-02-09
- Last updated
- 2022-08-04
Locations
18 sites across 5 countries: Denmark, Finland, Netherlands, Norway, Sweden
Source: ClinicalTrials.gov record NCT02678299. Inclusion in this directory is not an endorsement.